Drugs in R&D View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

1999

PUBLISHER

Springer International Publishing

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/40268

Recent publications latest 20 shown

  • 2019-03-27 Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
  • 2019-03-26 Effects of Food on the Bioavailability of Amphetamine in Healthy Adults After Administration of SHP465 Mixed Amphetamine Salts Extended-Release Capsules
  • 2019-03-02 Ulcerative Colitis: Shifting Sands
  • 2019-03 Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey
  • 2019-03 Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change
  • 2019-03 Assessment of Taste and Grittiness of Riomet® ER Strawberry, Riomet® ER Grape, Riomet® Cherry, and Metformin Immediate-Release Tablets in Healthy Subjects
  • 2019-03 Should Cytochrome P450 Inducers be Used to Accelerate Clearance of Brodifacoum from Poisoned Patients?
  • 2019-03-01 S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study
  • 2019-03 Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
  • 2019-03 Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon
  • 2019-02-27 Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
  • 2018-12 Acknowledgement to Referees
  • 2018-12 Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
  • 2018-12 Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly
  • 2018-12 Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial
  • 2018-12 Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
  • 2018-12 Efficacy and Safety of Budesonide in the Treatment of Eosinophilic Esophagitis: Updated Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies
  • 2018-12 Isavuconazole Kinetic Exploration for Clinical Practice
  • 2018-12 Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes
  • 2018-12 Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H69000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Pharmacotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B21007", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Pharmacology/Toxicology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33002", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Internal Medicine", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.765", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "0.881", 
            "type": "Rating"
          }
        ], 
        "description": "

    Drugs in R&D publishes original research and reviews from all phases of drug development and on clinical use of drugs following approval.

    The journal was re-launched in 2010 as the first Open Access journal from Adis, making all content from 2010 onwards freely available online. Pre-2010 content is not available as Open Access.

    Drugs in R&D offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal\u2019s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager\u00ae, supported by a database of international experts. This database is shared with other Adis journals.

    Manuscripts submitted to the journal for publication will be subject to a $3,000 article processing charge (APC) upon acceptance. Adis Open Access enables you to make your journal article freely available to anyone, in exchange for payment of APC. This option allows you, the author, to retain the copyright of the article according to the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC) License, which does not permit commercial re-use of the article.

    ", "editor": [ { "familyName": "van Rensburg", "givenName": "Anton", "type": "Person" } ], "id": "sg:journal.1020803", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "1174-5886", "1179-6901" ], "license": "Fully Open Access", "name": "Drugs in R&D", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "20803" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "40268" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn99-39864" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "1174-5886/DRUGS IN R&D" ] }, { "name": "scopus_id", "type": "PropertyValue", "value": [ "21264" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "100883647" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "439979" ] } ], "publisher": { "name": "Springer International Publishing", "type": "Organization" }, "publisherImprint": "Adis", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1020803" ], "sdDataset": "journals", "sdDatePublished": "2021-01-20T04:59", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///pack/app/journals_20190313_sn_only.jsonl", "startYear": "1999", "type": "Periodical", "url": "http://link.springer.com/journal/40268" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1020803'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1020803'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1020803'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1020803'


     

    This table displays all metadata directly associated to this object as RDF triples.

    80 TRIPLES      21 PREDICATES      32 URIs      25 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1020803 schema:about sg:ontologies/product-market-codes/B21007
    2 sg:ontologies/product-market-codes/H33002
    3 sg:ontologies/product-market-codes/H69000
    4 schema:contentRating N0feb3b805d014eb0b7c69281b093023d
    5 Nc92766aa6037490b8183b9494716face
    6 schema:description <i></i><p><i>Drugs in R&amp;D</i> publishes original research and reviews from all phases of drug development and on clinical use of drugs following approval.</p><p>The journal was re-launched in 2010 as the first Open Access journal from Adis, making all content from 2010 onwards freely available online. Pre-2010 content is not available as Open Access.</p><p><i>Drugs in R&amp;D</i> offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.</p><p>Manuscripts submitted to the journal for publication will be subject to a $3,000 article processing charge (APC) upon acceptance. Adis Open Access enables you to make your journal article freely available to anyone, in exchange for payment of APC. This option allows you, the author, to retain the copyright of the article according to the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC) License, which does not permit commercial re-use of the article.</p>
    7 schema:editor Ndbf90233bb5441bc92de79c06173f91d
    8 schema:inLanguage en
    9 schema:isAccessibleForFree true
    10 schema:issn 1174-5886
    11 1179-6901
    12 schema:license Fully Open Access
    13 schema:name Drugs in R&D
    14 schema:productId N1bacdb81720c450998b7bcd1fe83ef6f
    15 N1e4530fb7075473f8c069af1ded67d19
    16 N211cdc876ef440cf832e2ab3051f8c13
    17 N271f6478b0f84f1b96ee982842dfdfd3
    18 N4d452b0b101d4433a5565da8873be40b
    19 Na49bf57e6efc44488b51b37bf183f1f6
    20 Ne3d27cce0fed4005a0046671687b9799
    21 schema:publisher N6baf872e1e9d4151822de30333d1c70a
    22 schema:publisherImprint Adis
    23 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1020803
    24 schema:sdDatePublished 2021-01-20T04:59
    25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    26 schema:sdPublisher N2b1251cbaf534076a69dce95a8eb7a5f
    27 schema:startYear 1999
    28 schema:url http://link.springer.com/journal/40268
    29 sgo:license sg:explorer/license/
    30 sgo:sdDataset journals
    31 rdf:type schema:Periodical
    32 N0feb3b805d014eb0b7c69281b093023d schema:author N1c47225bbbe347aa8b25b6c6af1fafcc
    33 schema:ratingValue 0.881
    34 rdf:type schema:Rating
    35 N1bacdb81720c450998b7bcd1fe83ef6f schema:name springer_id
    36 schema:value 40268
    37 rdf:type schema:PropertyValue
    38 N1c47225bbbe347aa8b25b6c6af1fafcc rdf:first sjr
    39 rdf:rest rdf:nil
    40 N1e4530fb7075473f8c069af1ded67d19 schema:name nsd_ids_id
    41 schema:value 439979
    42 rdf:type schema:PropertyValue
    43 N211cdc876ef440cf832e2ab3051f8c13 schema:name dimensions_id
    44 schema:value 20803
    45 rdf:type schema:PropertyValue
    46 N271f6478b0f84f1b96ee982842dfdfd3 schema:name wos_id
    47 schema:value 1174-5886/DRUGS IN R&D
    48 rdf:type schema:PropertyValue
    49 N2b1251cbaf534076a69dce95a8eb7a5f schema:name Springer Nature - SN SciGraph project
    50 rdf:type schema:Organization
    51 N32578351309241b8afcbe0a52d675c64 rdf:first snip
    52 rdf:rest rdf:nil
    53 N4d452b0b101d4433a5565da8873be40b schema:name lccn_id
    54 schema:value sn99-39864
    55 rdf:type schema:PropertyValue
    56 N6baf872e1e9d4151822de30333d1c70a schema:name Springer International Publishing
    57 rdf:type schema:Organization
    58 N9449394e32cc42a5aef752c025ada780 schema:familyName van Rensburg
    59 schema:givenName Anton
    60 rdf:type schema:Person
    61 Na49bf57e6efc44488b51b37bf183f1f6 schema:name scopus_id
    62 schema:value 21264
    63 rdf:type schema:PropertyValue
    64 Nc92766aa6037490b8183b9494716face schema:author N32578351309241b8afcbe0a52d675c64
    65 schema:ratingValue 0.765
    66 rdf:type schema:Rating
    67 Ndbf90233bb5441bc92de79c06173f91d rdf:first N9449394e32cc42a5aef752c025ada780
    68 rdf:rest rdf:nil
    69 Ne3d27cce0fed4005a0046671687b9799 schema:name nlm_unique_id
    70 schema:value 100883647
    71 rdf:type schema:PropertyValue
    72 sg:ontologies/product-market-codes/B21007 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    73 schema:name Pharmacology/Toxicology
    74 rdf:type schema:DefinedTerm
    75 sg:ontologies/product-market-codes/H33002 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    76 schema:name Internal Medicine
    77 rdf:type schema:DefinedTerm
    78 sg:ontologies/product-market-codes/H69000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    79 schema:name Pharmacotherapy
    80 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...